Kronos Bio, Inc (KRON)
followers
·
Follow
| Sector: | HEALTH CARE |
| Industry: | BIOTECHNOLOGY & LIFE SCIENCES |
| SIC: | PHARMACEUTICAL PREPARATIONS |
| CEO: | Norbert W. Bischofberger |
| Employees: | 100 |
| Web site: | kronosbio.com |
|
1300 S. EL CAMINO REAL, SUITE 400, SAN MATEO, CA, 94402
(650) 781-5200
| |
Are you looking for this stock instead?
| All 13F Filers | Prior | Change | Hedge Funds 1 | Prior | Change |
|---|
Kronos Bio, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of novel cancer therapeutics. Its lead product candidate is entospletinib (ENTO), an orally administered, selective spleen tyrosine kinase inhibitor for acute myeloid leukemia patients. The company was incorporated in 2017 and is headquartered in San Mateo, California.
Please log in first to see chart